Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Hyung‐Don Kim(University of Ulsan), Changhoon Yoo(Ulsan College)

Nature Medicine

February 19, 2024

10.1038/s41591-024-02824-y

Cited by 65

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1k

Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

|Journal of the Korean Gastric Cancer Association|2023|285

Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)

|Journal of the Korean Gastric Cancer Association|2025|96

Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer

|Nature Cancer|2023|46